FDA Authorizes Regeneron’s Covid-19 Antibody Cocktail Drug

Regeneron Pharmaceuticals Inc.’s Covid-19 antibody drug was authorized Saturday by U.S. health regulators, the second cleared this month to treat patients who aren’t hospitalized but are at high risk of developing severe disease.

The Food and Drug Administration cleared the antibody drug cocktail for use treating mild to moderate Covid-19 patients 12 years of age and older, including people older than 65 years.

Regeneron’s drug combines two lab-made antibodies designed to latch onto the novel coronavirus and prevent it from replicating and hijacking human cells. The treatment is still being tested in clinical trials, after being developed by Regeneron scientists in Tarrytown, N.Y., earlier this year.

In October, it was one of three pharmaceutical treatments given to President Trump for treatment of Covid-19. Mr. Trump later attributed his recovery to Regeneron’s drug. “They gave me Regeneron, and it was like, unbelievable. I felt good immediately,” he said.

The FDA said it authorized the drug’s emergency use, a kind of clearance the agency has been using during the pandemic to speed up access to medicines.

Source link
#FDA #Authorizes #Regenerons #Covid19 #Antibody #Cocktail #Drug

Leave a Reply

Your email address will not be published. Required fields are marked *